- Home
- NEGG vs MDWD Comparison
NEGG vs MDWD Comparison
Compare NEGG & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEGG
- MDWD
- Stock Information
- Founded
- NEGG 2001
- MDWD 2000
- Country
- NEGG United States
- MDWD Israel
- Employees
- NEGG N/A
- MDWD N/A
- Industry
- NEGG Other Specialty Stores
- MDWD Medicinal Chemicals and Botanical Products
- Sector
- NEGG Consumer Discretionary
- MDWD Health Care
- Exchange
- NEGG Nasdaq
- MDWD Nasdaq
- Market Cap
- NEGG 180.8M
- MDWD 184.8M
- IPO Year
- NEGG 2010
- MDWD 2014
- Fundamental
- Price
- NEGG $0.46
- MDWD $19.83
- Analyst Decision
- NEGG
- MDWD Strong Buy
- Analyst Count
- NEGG 0
- MDWD 1
- Target Price
- NEGG N/A
- MDWD $25.00
- AVG Volume (30 Days)
- NEGG 1.0M
- MDWD 65.3K
- Earning Date
- NEGG 08-29-2024
- MDWD 03-20-2025
- Dividend Yield
- NEGG N/A
- MDWD N/A
- EPS Growth
- NEGG N/A
- MDWD N/A
- EPS
- NEGG N/A
- MDWD N/A
- Revenue
- NEGG $1,391,833,000.00
- MDWD $19,720,000.00
- Revenue This Year
- NEGG $6.01
- MDWD $10.15
- Revenue Next Year
- NEGG N/A
- MDWD $25.62
- P/E Ratio
- NEGG N/A
- MDWD N/A
- Revenue Growth
- NEGG N/A
- MDWD N/A
- 52 Week Low
- NEGG $0.39
- MDWD $11.04
- 52 Week High
- NEGG $1.32
- MDWD $24.00
- Technical
- Relative Strength Index (RSI)
- NEGG 48.25
- MDWD 63.06
- Support Level
- NEGG $0.39
- MDWD $17.47
- Resistance Level
- NEGG $0.51
- MDWD $18.79
- Average True Range (ATR)
- NEGG 0.05
- MDWD 1.06
- MACD
- NEGG 0.01
- MDWD 0.14
- Stochastic Oscillator
- NEGG 44.64
- MDWD 96.41
About NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally.
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.